The CCDC25 Knockout A2780 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout population derived from the A2780 human ovarian endometrioid adenocarcinoma cell line, with targeted disruption of the CCDC25 gene. This loss-of-function model enables investigation of CCDC25-dependent cellular processes without clonal selection bias. The polyclonal format preserves genetic heterogeneity while ensuring robust knockout across the cell pool, making it suitable for reproducible functional assays in cancer research.
A2780 cells serve as a well-established epithelial ovarian carcinoma model, characterized by rapid growth and metastatic competence. These cells recapitulate key features of high-grade serous ovarian cancer, including peritoneal dissemination, and are widely employed in metastasis and drug sensitivity studies. The integration of CCDC25 knockout into this background allows precise dissection of neutrophil extracellular trap (NET)-mediated signaling pathways within a clinically relevant ovarian cancer context, addressing critical gaps in our understanding of tumor microenvironment interactions.
CCDC25 functions as a receptor for NET-DNA, triggering activation of integrin-linked kinase (ILK) and downstream ??-parvin. ILK phosphorylates ??-parvin, promoting focal adhesion assembly and actin remodeling, thus enhancing cell adhesion and migration. In A2780 cells, the CCDC25?CILK?C??-parvin axis relays NET signals to metastatic responses. Knockout of CCDC25 uncouples this link, enabling precise analysis of the pathway’s role in adhesion dynamics and metastatic potential.
Knockout of CCDC25 in A2780 cells abrogates NET-induced migration and focal adhesion turnover, underscoring the gene??s essential role in metastatic behaviour. This model permits detailed examination of tumor cell reliance on microenvironmental NETs, and facilitates screening of compounds that interfere with the CCDC25?CILK?C??-parvin pathway. The polyclonal nature of the knockout ensures that observed phenotypes are not artifacts of clonal selection, strengthening the translational relevance of findings.
These cells are suitable for Transwell migration assays, NET binding assays, western blotting for ILK and ??-parvin, and immunofluorescence staining of F-actin to visualize cytoskeletal changes. Additional applications include cell adhesion assays and in vivo mouse metastasis models, supporting anti-metastatic drug screening and target validation. By providing a reliable CCDC25 loss-of-function model in an ovarian cancer background, this product advances metastasis research and tumor microenvironment studies. For further assistance, contact Ascent Research.
